Concerning high protein levels of both MITF and CDK2 reported in five out of 12 melanoma cell lines [22] and the most significant correlation between MITF and CDK2 mRNA levels in melanoma tumor samples compared with other types of cancer [21], XL888 and BRAFV600 inhibitor combination is likely ineffective in a subset of patients. This evidence concerns the gene CDK2 and melanoma.